Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Wave Life Sci Ord Sh
(NQ:
WVE
)
5.710
-0.120 (-2.06%)
Streaming Delayed Price
Updated: 10:49 AM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Wave Life Sci Ord Sh
< Previous
1
2
Next >
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
August 12, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
August 01, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
June 25, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
June 12, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
May 09, 2024
Appointment builds on Wave’s recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of...
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
May 02, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
April 30, 2024
Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
April 23, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
March 27, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 06, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
February 28, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
February 27, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
January 23, 2024
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.
Via
MarketBeat
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
January 08, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
December 15, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
December 07, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
December 06, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
December 06, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
November 22, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
November 03, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
September 28, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
September 25, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
September 05, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.